ArticleHealthcare (Basel, Switzerland)2024
Core Legal Challenges for Medical 3D Printing in the EU.
Article in Healthcare (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- When will bioprinting become a therapy? Translational and regulatory challenges in urogenital tissue engineering and surgery.Frontiers in bioengineering and biotechnology · 2026Article
- Current 3D Printing Technologies and their Potential Applications in Drug Delivery, Personalized Medicine & Pharmaceutical Sciences.Current drug discovery technologies · 2026Review
- Effect of print orientation of 3D-printed aligner templates on the volumetric accuracy of transferred composite attachments: an in vitro study.Clinical oral investigations · 2025Article
- Advances in 3D-Printed Drug Delivery and Screening Platforms for Bone Disease Therapy.Pharmaceutics · 2025Review
- Influence of geometry, reinforcement, and sterilisation on the dimensional accuracy of additively manufactured carbon fibre-reinforced nylon composites.Scientific reports · 2025Article
- To infinity and beyond: the promise of data-driven 3D printing of hernia mesh - a primer for surgeons.Hernia : the journal of hernias and abdominal wall surgery · 2025Review
- Impact of Disinfection and Sterilization on 3D-Printing Resin Performance for Surgical Guides in Cardiac Ablation Surgery.Bioengineering (Basel, Switzerland) · 2025Article
- Innovative 3D printing technologies and advanced materials revolutionizing orthopedic surgery: current applications and future directions.Frontiers in bioengineering and biotechnology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
3D printing has been adopted into routine use for certain medical applications, but more widespread usage has been hindered by, among other things, unclear legislation. We performed an analysis, using legal doctrinal study and legal informatics, of relevant EU legislation and case law in four issues relevant to medical 3D printing (excluding bioprinting or pharmacoprinting): pre-market approval, post-market liability, intellectual property rights, and data protection. Several gaps and uncertainties in the current legislation and interpretations were identified. In particular, we regard the current EU regulatory framework to be quite limiting and inflexible, exemplifying a cautionary approach common in EU law. Though the need to establish high safety standards in order to protect patients as a disadvantaged population is understood, both legal uncertainties and overregulation are seen as harmful to innovation. Hence, more adaptive legislation is called for to ensure continuous innovation efforts and enhanced patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.